<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4719">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01715402</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 11060</org_study_id>
    <nct_id>NCT01715402</nct_id>
  </id_info>
  <brief_title>Optimization of Health Expenditure in Liver Surgery</brief_title>
  <official_title>Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <authority>France: Commission nationale de l'informatique et des libertés</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to reduce the length of stay after liver surgery by taking account
      of objective quantitative clinical variables, subjective qualitative clinical variables and
      non clinical variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a new dimension of the activity expected of physicians is to improve the safety of care on
      the one hand and the control of health care costs on the other.

      key measures to help them are the publication of national recommendations, assessment of
      actual practices and the incentive to activity.

      Internationalwide recent and concordant data suggest that

        -  quality and security of care, after an initial improvement, are going to stall

        -  scientific recommendations are rarely validated by an impact analysis and are not
           applied

        -  clinical data collected within an administrative framework are unreliable and too
           generalist

        -  the evaluation, especially in the surgical field, is based on indicators sometimes
           irrelevant and often unclear
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>overall postoperative length of stay</measure>
    <time_frame>during the 3 months after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>the overall postoperative length of stay is defined as the hospitalization between the surgery and patient's discharge.
This period includes the readmission for at least 24 hours in case of outcomes related to the surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peroperative outcomes</measure>
    <time_frame>during the surgical procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the peroperative outcomes are collected during the surgery and correspond to any event occured during the surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative outcomes</measure>
    <time_frame>after the surgery until postoperative month 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the postoperative outcomes correspond to any event occured after the surgical intervention. These outcomes include fistulae; bleeding...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>construct of pronostic models</measure>
    <time_frame>after the postoperative month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>the construct of pronostic models include variables that affect the length of stay; morbidity and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of PMSI indicators</measure>
    <time_frame>after the postoperative month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>this evaluation includes the analysis of PMSI indicators; their validity and the influence of centres on hepatectomies results</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hilar Cholangiocarcinoma</condition>
  <condition>Intra Hepatic Cholangiocarcinoma</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>operated patients</arm_group_label>
    <description>this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>liver surgery</intervention_name>
    <description>this intervention type includes hepatectomies; wedge; segmentectomies etc...</description>
    <arm_group_label>operated patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the population corresponds to patients operated in one of the thirteen hospitals.

        These hospitals are distributed on the french territory to ensure that the recruitment is
        representative of the general population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective liver surgery

          -  older than 18

          -  agreed to participate

          -  surgical procedure included procedures registered as &quot;HLFA003 - 007 ; 009 - 011 ; 017
             - 020 ; HLFC002 à 004 ; 027 ; 032 ; 037&quot; in the PMSI database

        Exclusion Criteria:

          -  emergency surgery

          -  refused to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>olivier farges, MD, phD</last_name>
    <email>Olivier.farges@bjn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens North Hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean marc regimbeau, MD, PhD</last_name>
      <phone>+33 3 22 66 83 00</phone>
      <email>regimbeau.jean-marc@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>christophe laurent, MD, PhD</last_name>
      <phone>+33 5 56 79 56 79</phone>
      <email>christophe.laurent@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaujon University Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>olivier farges, MD, PhD</last_name>
      <phone>+33 1 40 87 50 00</phone>
      <email>Olivier.farges@bjn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille Regional Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pruvot francois rené, MD, PhD</last_name>
      <phone>+33 3 20 44 59 62</phone>
      <email>francois-rene.pruvot@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>christian ducerf, MD, PhD</last_name>
      <phone>+33472071631</phone>
      <email>christian.ducerf@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mustapha adham, MD, PhD</last_name>
      <phone>+33 4 72 11 62 61</phone>
      <email>mustapha.adham@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yves patrice letreut, MD, PhD</last_name>
      <phone>+33 4 91 38 38 58</phone>
      <email>yves-patrice.letreut@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paoli calmette institute</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean robert delpero, MD, PhD</last_name>
      <phone>+33 4-91-22-36-60</phone>
      <email>delperojr@marseille.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>francois paye, MD, PhD</last_name>
      <phone>+ 33 1 49 28 25 33</phone>
      <email>francois.paye@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>olivier soubrane, MD, PhD</last_name>
      <phone>+33 1 71 97 01 81</phone>
      <email>olivier.soubrane@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>philippe bachellier, MD, PhD</last_name>
      <phone>+33 3.88.12.71.71</phone>
      <email>philippe.bachellier@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy institute</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dominique elias, MD, PhD</last_name>
      <phone>+33 1 42 11 42 11</phone>
      <email>elias@igr.fr</email>
    </contact>
    <investigator>
      <last_name>diane goere, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paul Brousse Hospital</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>eric vibert, MD, PhD</last_name>
      <phone>+ 33 1 45 59 34 11</phone>
      <email>eric.vibert@pbr.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver tumor</keyword>
  <keyword>carcinoma</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>metastasis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin's Tumor</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
